# Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

> **NCT05158387** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1172 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Tozorakimab
- **DRUG:** Tozorakimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05158387
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-07
- **Primary completion:** 2026-01-19
- **Final completion:** 2026-03-22
- **Target enrollment:** 1172 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05158387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05158387, "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05158387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*